Format

Send to

Choose Destination
Iran J Pharm Res. 2018 Fall;17(4):1413-1419.

Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats.

Author information

1
Cellular and Molecular Research Center, Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
2
Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
3
Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
4
Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Abstract

The aim of this study is to evaluate the effects of pravastatin on Adriamycin (ADR)-induced nephropathy and the mechanisms involved. Forty rats were divided into the following 4 groups: control, ADR (15 mg.kg-1, IP), ADR plus pravastatin (20 mg.kg-1 which was started 5 days prior to ADR injection), and ADR plus pravastatin (20 mg.kg-1 which was started 5 days after ADR injection). On day 20 after ADR injection, the animals were sacrificed. The results showed that administration of pravastatin decreased the levels of 24-h urinary protein (24-h UP), blood urea nitrogen (BUN), and creatinine (p < 0.05) which had increased after the injection of ADR; in addition, pravastatin reversed structural changes seen in ADR group. Furthermore, pravastatin elevated mRNA and protein expression of nephrin (p < 0.05) which had been reduced in ADR group. We conclude that pravastatin protects and treats renal injury induced by ADR.

KEYWORDS:

Adriamycin; Nephropathy; Nephroprotective; Pravastatin; Rat

PMID:
30568699
PMCID:
PMC6269566

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center